EXCLUSIVE: Pasithea Therapeutics' Subsidiary Pasithea Clinics Reports It Has Been Approved To Provide Esketamine Nasal Spray (SPRAVATO) For Treatment-Resistant Depression In Adults
Portfolio Pulse from Benzinga Newsdesk
Pasithea Therapeutics' subsidiary, Pasithea Clinics, has received approval to provide Esketamine Nasal Spray (SPRAVATO) for treating adults with treatment-resistant depression.
November 23, 2021 | 12:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pasithea Therapeutics' subsidiary, Pasithea Clinics, has been approved to provide Esketamine Nasal Spray for treatment-resistant depression, potentially expanding its service offerings and market reach.
The approval allows Pasithea Clinics to offer a new treatment option, potentially increasing patient intake and revenue. This development is significant for KTTA as it enhances its service portfolio in the mental health sector.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90